
Haleon plc
HLNCF
Updated: 22/09/2026, 17:41:11
Haleon plc operates as a global consumer healthcare enterprise, actively involved in the research, development, production, and distribution of a diverse range of products. Its business activities cover extensive regions, including North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers various solutions such as oral hygiene products, pain management remedies, respiratory care items, digestive health aids, and a selection of vitamins, minerals, and supplements. Its notable brand collection features Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially named DRVW 2022 plc before officially rebranding to Haleon plc in February 2022. Its main office is situated in Brentford, United Kingdom.
No summaries found.
- Share price
- $4.60
- Market cap
- $40.51B
- Exchange
- OTC
- Currency
- USD
- CEO
- Brian James McNamara
- Employees
- 24,561
- IPO date
- 28/07/2022
- Beta
- 0.242
- Last dividend
- $0.00
- Day range
- $4.58 – $4.60
- 52-week range
- $4.15 – $5.75
- 1-day performance
- 2.00%
- 1-year performance
- 10.84%
- Current drawdown (1Y)
- -20.00%
- CIK
- 0001900304
- CUSIP
- N/A
- ISIN
- GB00BMX86B70
- Created
- 07/12/2025, 04:33:15
- Last update
- 22/09/2026, 17:41:11
Track Haleon plc with an AI analyst
See which prediction-market events move HLNCF, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
No news found for this symbol.